N/A
N=21
Olopatadine Eye Drops and Allergy Skin Testing
Allergic Rhinitis · Allergic Conjunctivitis
Bottom Line
View on ClinicalTrials.gov: NCT00775658 ↗Enrolled (actual)
21
Serious AEs
—
Results posted
Jul 2017
Primary outcome: Primary: The Difference in Area (cm2) of the Wheal Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo. — 0.461; 0.464 cm2 — p=0.57
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- olopatadine (Drug); placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Vanderbilt University Medical Center
- Primary completion
- Jun 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Difference in Area (cm2) of the Wheal Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo. |
0.461; 0.464 | 0.57 |
| PRIMARY The Difference in Area (cm2) of the Flare Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo. |
6.95; 8.31 | 0.09 |
Summary
Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.
Eligibility Criteria
Inclusion Criteria
- Adults aged 18 to 75 years
- Healthy volunteers (no major illnesses or active symptoms)
Exclusion Criteria
- Known allergy or hypersensitivity to the drugs or components
- Pregnant or nursing women
- Women wishing to become pregnant during the study's duration
- Use of topical or oral medications with antihistaminic activity for 14 days proceeding randomization
- Dermatographism as evidenced on skin testing on visit 1
- Chronic urticaria active within the past 6 months
- Severe hypertension
- Psychiatric diagnoses which could potentially affect medication compliance, such as schizophrenia or delusional disorders, as determined by the investigator obtaining informed consent and based on the subject's past medical history
- Inability to provide informed consent
Data sourced from ClinicalTrials.gov (NCT00775658). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.